Ethyl carbamate - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Enzymes (3)

Enzymes (3)Biointeractions (3)

Identification

Name

Ethyl carbamate

Accession Number

DB04827

Type

Small Molecule

Groups

Withdrawn

Description

Ethyl carbamate (also known as urethan and urethane), formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Aethylcarbamat

Aethylurethan

Carbamic acid ethyl ester

Carbamidsaeure-aethylester

Estane 5703

Ethyl ester of carbamic acid

Ethyl urethan

Ethyl urethane

Ethylcarbamate

Ethylester kyseliny karbaminove

Ethylurethan

Ethylurethane

O-ethyl urethane

O-ethylurethane

Uretan

Uretan etylowy

Uretano

Urethan

Urethane

Urethanum

External IDs

NSC-746

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Leucethane	Not Available
Leucothane	Not Available
Pracarbamin	Not Available
Pracarbamine	Not Available

Brand mixtures

Not Available

Categories

UNII

3IN71E75Z5

CAS number

51-79-6

Weight

Average: 89.0932
Monoisotopic: 89.047678473

Chemical Formula

C₃H₇NO₂

InChI Key

JOYRKODLDBILNP-UHFFFAOYSA-N

InChI

InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)

IUPAC Name

ethyl carbamate

SMILES

CCOC(N)=O

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl carbamate.	Experimental
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine.	Approved, Investigational
Alfaxalone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl carbamate.	Approved, Illicit
Allopregnanolone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sage 547.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethyl carbamate.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate.	Approved, Illicit, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amperozide.	Experimental
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Asenapine.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azaperone.	Vet Approved
Azelastine	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.	Illicit
Benperidol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl carbamate.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benzyl alcohol.	Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Ethyl carbamate.	Approved, Investigational
Brexpiprazole	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.	Approved, Illicit
Brompheniramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate.	Approved, Investigational
Buprenorphine	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butamben.	Approved
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Ethyl carbamate.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate.	Approved, Illicit, Vet Approved
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Ethyl carbamate.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carisoprodol.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl carbamate.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethyl carbamate.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorphenamine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorzoxazone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clobazam.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.	Approved, Illicit
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl carbamate.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate.	Approved, Illicit
Cyclizine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.	Approved, Investigational
Cyproheptadine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desipramine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Ethyl carbamate.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl carbamate.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Ethyl carbamate.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl carbamate.	Approved, Illicit, Vet Approved
Difenoxin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Difenoxin.	Approved, Illicit
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Ethyl carbamate.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Ethyl carbamate.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate.	Approved, Illicit
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.	Approved, Investigational
Doramectin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doramectin.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxepin.	Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with DPDPE.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Ethyl carbamate.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Ethyl carbamate.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Ethyl carbamate.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Entacapone.	Approved, Investigational
Escitalopram	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl carbamate.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate.	Approved
Ethanol	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethotoin.	Approved
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl carbamate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fexofenadine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flibanserin.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl carbamate.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl carbamate.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fospropofol.	Approved, Illicit
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethyl carbamate.	Approved, Illicit
Gepirone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Ethyl carbamate.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Ethyl carbamate.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Ethyl carbamate.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate.	Approved
Hydrocodone	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.	Investigational, Withdrawn
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Ethyl carbamate.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethyl carbamate.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate.	Approved, Vet Approved
Lithium	The risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lofentanil.	Illicit
Loratadine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl carbamate.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Maprotiline.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meclizine.	Approved
Medetomidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medetomidine.	Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Ethyl carbamate.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethyl carbamate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate.	Approved
Methotrimeprazine	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethyl carbamate.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate.	Approved
Metyrosine	Ethyl carbamate may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Investigational
Mirtazapine	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate.	Approved
Nefazodone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nefazodone.	Approved, Withdrawn
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl carbamate.	Approved, Investigational
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Ethyl carbamate.	Experimental
Olopatadine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate.	Approved
Opium	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Opium.	Approved, Illicit
Orphenadrine	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.	Investigational
Ouabain	Ouabain may decrease the cardiotoxic activities of Ethyl carbamate.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl carbamate.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate.	Approved, Investigational, Vet Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.	Approved, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.	Approved
Paraldehyde	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved
Perazine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate.	Approved
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoxyethanol.	Approved
Phenytoin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Piritramide.	Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pizotifen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.	Approved
Pramipexole	Ethyl carbamate may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl carbamate.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Ethyl carbamate.	Approved
Primidone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Ethyl carbamate.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.	Approved
PSD502	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with PSD502.	Investigational
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ramelteon.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ritanserin.	Investigational
Romifidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Romifidine.	Vet Approved
Ropinirole	Ethyl carbamate may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate.	Approved
Rotigotine	Ethyl carbamate may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl carbamate.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.	Approved, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.	Approved
Suvorexant	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tasimelteon.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrodotoxin.	Investigational
Thalidomide	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiapride.	Approved, Investigational
Tiletamine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiletamine.	Vet Approved
Tizanidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tolcapone.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl carbamate.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.	Approved
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Ethyl carbamate.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Triprolidine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethyl carbamate.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Venlafaxine.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vigabatrin.	Approved
Vortioxetine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine.	Approved
Xylazine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zolazepam.	Vet Approved
Zolpidem	Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Ethyl carbamate.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Norton A. Cashen, "Method of producing anhydrous crystalline reaction products of formaldehyde and methyl-, ethyl carbamate." U.S. Patent US4002668, issued July, 1973.

US4002668

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB31219
KEGG Compound	C01537
PubChem Compound	5641
PubChem Substance	46505215
ChemSpider	5439
ChEBI	17967
ChEMBL	CHEMBL462547
Wikipedia	Urethane

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	49 °C	PhysProp
boiling point (°C)	185 °C	PhysProp
water solubility	4.8E+005 mg/L (at 15 °C)	SEIDELL,A (1941)
logP	-0.15	HANSCH,C ET AL. (1995)
logS	0.85	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	371.0 mg/mL	ALOGPS
logP	-0.14	ALOGPS
logP	-0.054	ChemAxon
logS	0.62	ALOGPS
pKa (Strongest Acidic)	15.47	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	1	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	52.32 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	20.84 m³·mol^-1	ChemAxon
Polarizability	8.64 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9922
Caco-2 permeable	+	0.516
P-glycoprotein substrate	Non-substrate	0.892
P-glycoprotein inhibitor I	Non-inhibitor	0.9593
P-glycoprotein inhibitor II	Non-inhibitor	0.9677
Renal organic cation transporter	Non-inhibitor	0.9397
CYP450 2C9 substrate	Non-substrate	0.8579
CYP450 2D6 substrate	Non-substrate	0.7888
CYP450 3A4 substrate	Non-substrate	0.7321
CYP450 1A2 substrate	Non-inhibitor	0.5553
CYP450 2C9 inhibitor	Non-inhibitor	0.9306
CYP450 2D6 inhibitor	Non-inhibitor	0.9168
CYP450 2C19 inhibitor	Non-inhibitor	0.9537
CYP450 3A4 inhibitor	Non-inhibitor	0.9765
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9452
Ames test	AMES toxic	0.7773
Carcinogenicity	Non-carcinogens	0.6285
Biodegradation	Ready biodegradable	0.6313
Rat acute toxicity	1.6607 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9864
hERG inhibition (predictor II)	Non-inhibitor	0.9783

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (8.45 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
GC-MS	GC-MS Spectrum - EI-B	splash10-01r7-9000000000-ba57e1f4b939a6bb2c1c	View in MoNA
GC-MS	GC-MS Spectrum - EI-B	splash10-01r7-9000000000-4905daa85aa870eff5d7	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-01r7-9000000000-dbaaf921e6f73cb42292	View in MoNA
1D NMR	1H NMR Spectrum	Not Available
1D NMR	13C NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as carboximidic acids and derivatives. These are compounds containing a carboximidic group, with the general formula R-C(=NR1)OR2.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic acids and derivatives

Sub Class

Carboximidic acids and derivatives

Direct Parent

Carboximidic acids and derivatives

Alternative Parents

Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives

Substituents

Carboximidic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Imine / Aliphatic acyclic compound

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

carbamate ester (CHEBI:17967 ) / a small molecule (URETHAN )

Enzymes

Details

1. Cytosolic phospholipase A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Phospholipase a2 activity
Specific Function:: Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:: PLA2G4A
Uniprot ID:: P47712
Uniprot Name:: Cytosolic phospholipase A2
Molecular Weight:: 85238.2 Da

References

Dinnes DL, Santerre JP, Labow RS: Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9. [PubMed:15626436 ]
Labow RS, Santerre JP, Waghray G: The effect of phospholipids on the biodegradation of polyurethanes by lysosomal enzymes. J Biomater Sci Polym Ed. 1997;8(10):779-95. [PubMed:9297603 ]

Details

2. Myeloperoxidase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Peroxidase activity
Specific Function:: Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:: MPO
Uniprot ID:: P05164
Uniprot Name:: Myeloperoxidase
Molecular Weight:: 83867.71 Da

References

Kotanidou A, Choi AM, Winchurch RA, Otterbein L, Fessler HE: Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-alpha release. J Appl Physiol (1985). 1996 Nov;81(5):2305-11. [PubMed:8941558 ]

Details

3. Aldehyde oxidase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xanthine dehydrogenase activity
Specific Function:: Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:: AOX1
Uniprot ID:: Q06278
Uniprot Name:: Aldehyde oxidase
Molecular Weight:: 147916.735 Da

References

Sugihara K, Kitamura S, Tatsumi K: Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. J Pharmacobiodyn. 1983 Sep;6(9):677-83. [PubMed:6689178 ]

Drug created on September 11, 2007 14:32 / Updated on September 01, 2017 11:22

Structure for DB04827 (Ethyl carbamate)

Enzymes

References

References

References